Navigation Links
China-Biotics Provides Further Updates on Qingpu New Facility
Date:7/7/2010

SHANGHAI, July 7 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics", the "Company") (Nasdaq: CHBT), the leading developer, manufacturer and distributor of probiotics products in China, today provides further updates on the Company's bulk additive operation.

China-Biotics gained more bulk customers during the quarter ended at June 30, 2010 and the total number of bulk customers increased to 39 by the end of June. Among the 39 customers, 4 are animal feed producers and the remaining are dairy enterprises.

During the quarter, the Qingpu facility produced over 15 metric tons of bulk probiotics products and production utilization rate for the Qingpu bulk additive facility has steadily ramped up to over 60 metric tons per year.

Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics, commented, "We are pleased with the progress on our bulk business in the first quarter fiscal year 2011. We have not only increased the number of customers but ramped up our production utilization rate as well. We remain focused on building long-term relationships with dairy companies as they are moving towards high value-added products to meet market demand and consumer preferences. In such a favorite environment, we believe that we are well positioned to expand our business and gain market share. We look forward to further expanding our production to meet the bulk market demand in the coming quarters."

About China-Biotics

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company develops and produces its proprietary product portfolio including live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," or "continue," the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 17 and elsewhere in the Company's 2010 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward-looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

    For more information, please contact:

     Travis Cai
     Chief Financial Officer
     China-Biotics, Inc.
     Email: traviscai@chn-biotics.com

     Kevin Theiss
     Grayling
     Phone: +1-646-284-9409
     Email: kevin.theiss@grayling.com


'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
3. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
4. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
5. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
6. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
7. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
8. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
9. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
10. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
11. China-Biotics, Inc. Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time in ... STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, ... , US2020’s mission is to change the trajectory of STEM education in America ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):